Optimize Formulation of VSA Adjuvant

NIH RePORTER · NIH · N43 · $600,000 · view on reporter.nih.gov ↗

Abstract

The contract supports the development of a saponin as a vaccine adjuvant. The adjuvant development activities are being conducted within the context of vaccines to protect against SARS-CoV-2 and pneumococcal infection.

Key facts

NIH application ID: 10678489
Project number: 75N93022C00033-0-9999-1
Recipient: ADJUVAX LLC
Principal Investigator: DAVID CLEMENTS
Activity code: N43
Funding institute: NIH
Fiscal year: 2022
Award amount: $600,000
Award type: —
Project period: 2022-07-05 → 2024-07-05